Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-19T15:02:13.771Z Has data issue: false hasContentIssue false
  • English
  • Français

Balancing Efficacy and Safety in Treatment with Antipsychotics

Published online by Cambridge University Press:  07 November 2014

Christoph U. Correll
Christoph U. Correll*
Affiliation:
Dr. Correll is medical director of the Recognition and Prevention Program at the, Zucker Hillside Hospital, in Queens, New York
*
Christoph U. Correll, MD, The Zucker Hillside Hospital, Psychiatry Research, 75-59 263rd St, Glen Oaks, NY, 11004. Tel: 718-470-4812; Fax: 718-343-1659; E-mail: ccorrell@lij.edu.
Get access Rights & Permissions [Opens in a new window]

Abstract

Balancing efficacy with tolerability and safety of prescribed treatments is critical to optimizing antipsychotic treatment outcomes in the mentally ill. Symptom control, symptom remission, and functional recovery are only realistic goals when treatments are both effective and well tolerated. The consideration of predictable differences in antipsychotic adverse-effect profiles is central to successful illness management. Minimizing adverse effects on alertness, motivation, cognition, sexual/reproductive functioning, and physical health enhancesmental health outcomes, partly through improving treatment adherence. Neuroendocrine and metabolic side effects of antipsychotics for cardiovascular morbidity and mortality need to be addressed proactively and aggressively. In view of the widespread lack of primary care engagement and the adverse effects of psychotropic medications on cardiovascular health, psychiatric care providers should function as key facilitators of an integrated mental and physical health management approach. In addition to psychoeducation and healthy lifestyle counseling, clinicians can improve psychiatric and physical health by selecting medications carefully, routinely screening and monitoring for reversible cardiovascular risk factors, and playing an active role in the prevention and interdisciplinary management of cardiovascular risk factors and medical illness in the vulnerable mentally ill.

Type
Research Article
Information
CNS Spectrums , Volume 12 , Issue S17 , 2007 , pp. 12 - 20
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kane, JM. Treatment adherence and long-term outcomes. CNS Spectr. 2007;12(10 suppl 17):21–26.Google Scholar
2.Knowler, WC, Barrett-Connor, E, Fowler, SE, et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.Google Scholar
3.Coombes, RC, Hall, E, Gibson, LJ, et al.A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–1092.Google Scholar
4.Davis, JM, Chen, N, Glick, ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553–564.CrossRefGoogle ScholarPubMed
5.Heres, S, Davis, J, Maino, K, et al.Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163(2):185–194.CrossRefGoogle ScholarPubMed
6.Woods, SW, Gueorguieva, RV, Baker, CB, et al.Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Arch Gen Psychiatry. 2005;62(9):961–970.Google Scholar
7.Kemmler, G, Hummer, M, Widschwendter, C, et al.Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62(12):1305–1312.Google Scholar
8.Perlis, RH, Welge, JA, Vornik, LA, et al.Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67(4):509–516.Google Scholar
9.Scherk, H, Pajonk, FG, Leucht, S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442–455.CrossRefGoogle Scholar
10.Lieberman, JA, Stroup, TS, McEvoy, JP, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.Google Scholar
11.Jones, PB, Barnes, TR, Davies, L, et al.Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079–1087.CrossRefGoogle Scholar
12.Leucht, S, Barnes, TR, Kissling, W, et al.Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 20031;160(7):1209–1222.Google Scholar
13.Schooler, N, Rabinowitz, J, Davidson, M, et al.Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162(5):947–953.CrossRefGoogle Scholar
14.Woerner, MG, Robinson, DG, Alvir, JM, et al.Clozapine as a first treatment for schizophrenia. Am J Psychiatry. 2003;160(8):1514–1516.Google Scholar
15.Agid, O, Remington, G, Kapur, S, et al.Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27(4):369–373.CrossRefGoogle ScholarPubMed
16.March, JS, Silva, SG, Compton, S, et al.The case for practical clinical trials in psychiatry. Am J Psychiatry. 2005;162(5):836–846.Google Scholar
17.Essock, SM, Covell, NH, Davis, SM, et al.Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090–2095.Google Scholar
18.Stroup, TS, Lieberman, JA, McEvoy, JP, et al.Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007;164(3):415–427.Google Scholar
19.Leucht, S, Pitschel-Walz, G, Abraham, D, et al.Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51–68.Google Scholar
20.Tarsy, D, Baldessarini, RJ, Tarazi, FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16(1):23–45.Google Scholar
21.Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):4144–4425.Google Scholar
22.Marder, SR, McQuade, RD, Stock, E, et al.Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2-3):123–136.Google Scholar
23.Weiden, PJ, Miller, AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract. 2001;7(1):41–47.Google Scholar
24.Physician's Desk Reference. 58th ed. Montvale, NJ: Thomson PDR; 2004.Google Scholar
25.McQuade, RD, Stock, E, Marcus, R, et al.A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65(suppl 18):47–56.Google ScholarPubMed
26.Addington, DE, Pantelis, C, Dineen, M, et al.Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry. 2004;65(12):1624–1633.Google Scholar
27.Conley, RR, Mahmoud, R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158(5):765–774.CrossRefGoogle ScholarPubMed
28.Azorin, JM, Spiegel, R, Remington, G, et al.A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001;158(8):1305–1313.Google Scholar
29.Meltzer, HY, Alphs, L, Green, AI, et al.Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91.Google Scholar
30.Yatham, LN, Paulsson, B, Mullen, J, et al.Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004;24(6):599–606.Google Scholar
31.Vieta, E, Parramon, G, Padrell, E, et al.Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2002;4(5):335–340.Google Scholar
32.Marder, SR, Kramer, M, Ford, L, et al.Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry. 2007 Jun 27; [Epub ahead of print]Google Scholar
33.Haddad, PM, Wieck, A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291–2314.CrossRefGoogle ScholarPubMed
34.Correll, CU, Carlson, HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45(7):771–791.Google Scholar
35.Kane, J, Canas, F, Kramer, M, et al.Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1-3):147–161.CrossRefGoogle ScholarPubMed
36.Nakonezny, PA, Byerly, MJ, Rush, AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther. 2007;33(3):203–216.Google Scholar
37.O'Keane, V, Meaney, AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005;25(1):26–31.Google Scholar
38.Howard, L, Kirkwood, G, Leese, M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007;190:129–134.Google Scholar
39.Serri, O, Li, L, Mamputu, JC, Beauchamp, MC, et al.The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006;64(4):366–370.Google Scholar
40.Szarfman, A, Tonning, JM, Levine, JG, et al.Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006;26(6):748–758.Google Scholar
41.Clevenger, CV, Furth, PA, Hankinson, SE, et al.The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24(1):1–27.Google Scholar
42.Eliassen, AH, Tworoger, SS, Hankinson, SE. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women. Int J Cancer. 2007;120(7):1536–4151.Google Scholar
43.Shim, JC, Shin, JG, Kelly, DL, et al.Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007 Sep;164(9):1404–1410.Google Scholar
44.Colton, CW, Manderscheid, RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):A42.Google Scholar
45.Allison, DB, Fontaine, KR, Heo, M, et al.The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60(4):215–220.Google Scholar
46.Fagiolini, A, Frank, E, Scott, JA, et al.Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7(5):424–430.Google Scholar
47.McElroy, SL, Frye, MA, Suppes, T, et al.Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63(3):207–213.Google Scholar
48.Hennekens, CH, Hennekens, AR, Hollar, D, et al.Schizophrenia and increased risk of cardiovascular disease. Am Heart J. 2005;150(6):1115–1121.Google Scholar
49.Davidson, S, Judd, F, Jolley, D, et al.Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35(2):196–202.CrossRefGoogle ScholarPubMed
50.Goff, DC, Sullivan, LM, McEvoy, JP, et al.A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80(1):45–53.Google Scholar
51.Dixon, L, Postrado, L, Delahanty, J, et al.The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis. 1999;187(8):496–502.Google Scholar
52.Cassidy, F, Ahearn, E, Carroll, BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry. 1999;156(9):1417–1420.Google Scholar
53.Kilbourne, AM, Cornelius, JR, Han, X, et al.Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 2004;6(5):368–373.Google Scholar
54.Herran, A, de Santiago, A, Sandoya, M, et al.Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr Res. 2000;41(2):373–381.Google Scholar
55.Ucok, A, Polat, A, Bozkurt, O, et al.Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci. 2004;58(4):434–437.Google Scholar
56.Allebeck, P. Schizophrenia: a life-shortening disease. Schizophr Bull. 1989;15(1):81–89.Google Scholar
57.Koro, CE, Fedder, DO, L'Italien, GJ, et al.An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59(11):1021–1026.Google Scholar
58.Nasrallah, HA, Meyer, JM, Goff, DC, et al.Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1-3):15–22.Google Scholar
59.Meyer, J, Koro, CE, L'Italien, GJ. The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry. 2005;17(3):173–180.Google Scholar
60.McEvoy, JP, Meyer, JM, Goff, DC, et al.Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32.Google Scholar
61.Cohn, T, Prud'homme, D, Streiner, D, et al.Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49(11):753–760.Google Scholar
62.Kato, MM, Currier, MB, Gomez, CM, et al.Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004;6(2):74–77.Google Scholar
63.Heiskanen, T, Niskanen, L, Lyytikainen, R, et al.Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64(5):575–579.Google Scholar
64.Garcia-Portilla, MP, Saiz, PA, Benabarre, A, et al.The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2007 Jul 11; [Epub ahead of print]Google Scholar
65.Birkenaes, AB, Opjordsmoen, S, Brunborg, C, et al.The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68(6):917–923.Google Scholar
66.Yumru, M, Savas, HA, Kurt, E, et al.Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2007;98(3):247–522. Epub 2006 Sep 12.Google Scholar
67.Cardenas, J, Frye, MA, Marusak, SL, et al.Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2007 Jul 10; [Epub ahead of print]Google Scholar
68.Correll, CU, Frederickson, AM, Kane, JM, et al.Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry. 2006;67(4):575–583.Google Scholar
69.De Hert, M, van Winkel, R, Van Eyck, D, et al.Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health. 2006;27(2):14.Google Scholar
70.Lambert, TJ, Velakoulis, D, Pantelis, C. Medical comorbidity in schizophrenia. Med J Aust. 2003;178(Suppl):S67–70.Google Scholar
71.Correll, CU, Malhotra, AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl). 2004;174(4):477–489.Google Scholar
72.Bergman, RN, Ader, M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry. 2005;66(4):504–514.Google Scholar
73.American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.Google Scholar
74.Newcomer, JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1–93.Google Scholar
75.Stroup, TS, Lieberman, JA, McEvoy, JP, et al.Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611–622.Google Scholar
76.Zipursky, RB, Gu, H, Green, AI, et al.Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537–543.Google Scholar
77.McEvoy, JP, Lieberman, JA, Perkins, DO, et al.Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–1060.Google Scholar
78.Chrzanowski, WK, Marcus, RN, Torbeyns, A, et al.Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006;189(2):259–266.Google Scholar
79.Simpson, GM, Glick, ID, Weiden, PJ, et al.Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(10):1837–1847.Google Scholar
80.Buckley, PF, Miller, DD, Singer, B, et al.Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res. 2005;79(2-3):281–288.Google Scholar
81.Newcomer, JW, Nasrallah, HA, Loebel, AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol. 2004;24(5 suppl 1):S1–S6.Google Scholar
82.Weissman, EM, Zhu, CW, Schooler, NR, et al.Lipid monitoring in patients with schizophrenia prescribed second-generationantipsychotics. J Clin Psychiatry. 2006;67(9):1323–1326.Google Scholar
83.Kilbourne, AM, Post, EP, Bauer, MS, et al.Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. J Affect Disord. 2007;102(1-3):145–151.CrossRefGoogle ScholarPubMed
84.Suppes, T, McElroy, SL, Hirschfeld, R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. Psychopharmacol Bull. 2007;40(2):22–37; quiz 38-40.Google Scholar
85.Correll, CU, Harris, JL, Pantaleon Moya, RA, et al.Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: missed targets and lost opportunities. Schizophr Res. 2007;92(1-3):103–107.Google Scholar
86.Frye, RL. Optimal care of patients with type 2 diabetes mellitus and coronary artery disease. Am J Med. 2003;115(suppl 8A):S93–S98.Google Scholar
87.Druss, BG, Bradford, WD, Rosenheck, RA, et al.Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry. 2001;58(6):565–572.Google Scholar
88.Marder, SR, Essock, SM, Miller, AL, et al.Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334–1349.Google Scholar
89.Cuffel, B, et al. Poster presented at: The 58th Institute on Psychiatric Services Annual Meeting; October 5-8, 2006; New York, NY.Google Scholar
90.Kinon, BJ, Kaiser, CJ, Ahmed, S, et al.Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25(3):255–258.CrossRefGoogle ScholarPubMed
91.Straker, D, Correll, CU, Kramer-Ginsberg, E, et al.Cost-effective screening for metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry. 2005;162(6):1217–1221.CrossRefGoogle ScholarPubMed
92.Faulkner, G, Cohn, T, Remington, G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev. 2007;(1):CD005148.Google Scholar
93.Correll, CU. Real life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006;67(1):160–161.Google Scholar
94.Meyer, JM, Pandina, G, Bossie, CA, et al.Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther. 2005;27(12):1930–1941.Google Scholar
95.Weiden, PJ, Simpson, GM, Potkin, SG, et al.Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64(5):580–588.Google Scholar
96.Weiden, PJ, Newcomer, JW, Loebel, AD, et al.Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2007 Jul 18; [Epub ahead of print].Google Scholar
97.De Hert, M, Hanssens, L, van Winkel, R, et al.A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull. 2007;33(3):823–830.Google Scholar
98.Casey, DE, Carson, WH, Saha, AR, et al.Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166(4):391–399.Google Scholar
99.Henderson, DC, Copeland, PM, Daley, TB, et al.A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005;162(5):954–962.Google Scholar
100.Klein, DJ, Cottingham, EM, Sorter, M, et al.A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072–2079.Google Scholar
101.Li, TY, Rana, JS, Manson, JE, et al.Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation. 2006;113(4):499–506.CrossRefGoogle ScholarPubMed
102.Hennekens, CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 1998;97(11):1095–1102.Google Scholar
103.Rich-Edwards, JW, Manson, JE, Hennekens, CH, Buring, JE. The primary prevention of coronary heart disease in women. N Engl J Med. 1995;332(26):1758–1766.Google Scholar
104.Bassuk, SS, Manson, JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol. 2005;99(3):1193–1204.Google Scholar
105.Grundy, SM, Cleeman, JI, Merz, CN. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239.Google Scholar
106.Critchley, JA, Capewell, S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290(1):86–97.Google Scholar
107.Manson, JE, Tosteson, H, Ridker, PM, et al.The primary prevention of myocardial infarction. N Engl J Med. 1992;326(21):1406–1416.Google Scholar
108.De Hert, M, Kalnicka, D, van Winkel, R, et al.Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2006;67(12):1889–1896.Google Scholar